Widget Image
Follow PPD Social Media
Wednesday, December 11, 2024
HomeNewsWorldCOVID-19 Testing in US to Double South Korea on Per Capita Basis

COVID-19 Testing in US to Double South Korea on Per Capita Basis

Researcher holds test tube with coronavirus virus (COVID-19), analysis and medicine to fight the epidemic. (Photo: AdobeStock)

White House Touts COVID-19 Testing Advancements and Capabilities

Researcher holds test tube with coronavirus virus (COVID-19), analysis and medicine to fight the epidemic. (Photo: AdobeStock)
Researcher holds test tube with coronavirus virus (COVID-19), analysis and medicine to fight the epidemic. (Photo: AdobeStock)

Washington, D.C. (PPD) — On Monday, the number of coronavirus (COVID-19) tests conducted in the U.S. will exceed 9 million, more than twice South Korea on a per capita basis.

Global public health officials and administration critics characterized South Korea as the gold standard in COVID-19 testing and overall pandemic response. The former was thought to largely dictate the success of the latter.

“No other country in the world comes close to the numbers,” Assistant Secretary for Health Admiral Brett Giroir said during a press conference at the White House. “Everyone talks about South Korea being the standard. Today we will have done more than twice the per capita rate of testing that was accomplished in South Korea.”

“No matter how you look at it, America is leading the world in testing.”

South Korea conducted 663,886 COVID-19 tests as of Monday. As of 2018, the population of was roughly 51.64 million. That compares to 328.2 million in the U.S. as of 2019.

Written by

People's Pundit Daily delivers reader-funded data journalism covering the latest news in politics, polls, elections, business, the economy and markets.

No comments

leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

People's Pundit Daily
You have %%pigeonMeterAvailable%% free %%pigeonCopyPage%% remaining this month. Get unlimited access and support reader-funded, independent data journalism.

Start a 14-day free trial now. Pay later!

Start Trial